UK Regulators Withhold Support for Astra Breast-Cancer Drug
AstraZeneca Plc and Daiichi Sankyo Co. failed to win immediate endorsement for an additional use for their breast cancer medicine from England’s drug-cost regulator, a potential blow to the companies’ efforts to expand sales of one of their most promising therapies.









